AAAAAA

   
Results: 1-25 | 26-35
Results: 1-25/35
Aging lowers steady-state antioxidant enzyme and stress protein expressionin primary hepatocytes
Authors: Hall, DM Sattler, GL Sattler, CA Zhang, HJ Oberley, LW Pitot, HC Kregel, KC
Citation: Dm. Hall et al., Aging lowers steady-state antioxidant enzyme and stress protein expressionin primary hepatocytes, J GERONT A, 56(6), 2001, pp. B259-B267
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks
Authors: Alberts, SR Erlichman, C Sloan, J Okuno, SH Burch, PA Rubin, J Pitot, HC Goldberg, RM Adjei, AA Atherton, PJ Kaufmann, SH
Citation: Sr. Alberts et al., Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks, ANN ONCOL, 12(5), 2001, pp. 627-631
Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
Authors: Erlichman, C Adjei, AA Alberts, SR Sloan, JA Goldberg, RM Pitot, HC Rubin, J Atherton, PJ Klee, GG Humphrey, R
Citation: C. Erlichman et al., Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566, ANN ONCOL, 12(3), 2001, pp. 389-395
Future directions in adjuvant therapy for stage III colon carcinoma
Authors: Pitot, HC Goldberg, RM
Citation: Hc. Pitot et Rm. Goldberg, Future directions in adjuvant therapy for stage III colon carcinoma, ONCOLOGY-NY, 15(3), 2001, pp. 31-36
Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen
Authors: Divi, RL Dragan, YP Pitot, HC Poirier, MC
Citation: Rl. Divi et al., Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen, CARCINOGENE, 22(10), 2001, pp. 1693-1699
Pathways of progression in hepatocarcinogenesis
Authors: Pitot, HC
Citation: Hc. Pitot, Pathways of progression in hepatocarcinogenesis, LANCET, 358(9285), 2001, pp. 859-860
A clonal growth model: Time-course simulations of liver foci growth following penta- or hexachlorobenzene treatment in a medium-term bioassay
Authors: Ou, YC Conolly, RB Thomas, RS Xu, YH Andersen, ME Chubb, LS Pitot, HC Yang, RSH
Citation: Yc. Ou et al., A clonal growth model: Time-course simulations of liver foci growth following penta- or hexachlorobenzene treatment in a medium-term bioassay, CANCER RES, 61(5), 2001, pp. 1879-1889
A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors
Authors: Ansell, SM Pitot, HC Burch, PA Kvols, LK Mahoney, MR Rubin, J
Citation: Sm. Ansell et al., A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors, CANCER, 91(8), 2001, pp. 1543-1548
Priming tissue-specific cellular immunity in a phase I trial of autologousdendritic cells for prostate cancer
Authors: Burch, PA Breen, JK Buckner, JC Gastineau, DA Kaur, JA Laus, RL Padley, DJ Peshwa, MV Pitot, HC Richardson, RL Smits, BJ Sopapan, P Strang, G Valone, FH Vuk-Pavlovic, S
Citation: Pa. Burch et al., Priming tissue-specific cellular immunity in a phase I trial of autologousdendritic cells for prostate cancer, CLIN CANC R, 6(6), 2000, pp. 2175-2182
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
Authors: Pitot, HC Goldberg, RM Reid, JM Sloan, JA Skaff, PA Erlichman, C Rubin, J Burch, PA Adjei, AA Alberts, SA Schaaf, LJ Elfring, G Miller, LL
Citation: Hc. Pitot et al., Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy, CLIN CANC R, 6(6), 2000, pp. 2236-2244
Genome-wide loss of heterozygosity analysis of chemically induced rat hepatocellular carcinomas reveals elevated frequency of allelic imbalances on chromosomes 1, 6, 8, 11, 15, 17, and 20
Authors: Teeguarden, JG Newton, MA Dragan, YP Pitot, HC
Citation: Jg. Teeguarden et al., Genome-wide loss of heterozygosity analysis of chemically induced rat hepatocellular carcinomas reveals elevated frequency of allelic imbalances on chromosomes 1, 6, 8, 11, 15, 17, and 20, MOL CARCINO, 28(1), 2000, pp. 51-61
The Damjanov/Meropol article reviewed
Authors: Pitot, HC Goldberg, RM
Citation: Hc. Pitot et Rm. Goldberg, The Damjanov/Meropol article reviewed, ONCOLOGY-NY, 14(6), 2000, pp. 813-814
Multiple polypeptide hormone expression in pancreatic islet cell carcinomas derived from phosphoenolpyruvatecarboxykinase-SV40 T antigen transgenic rats
Authors: Haas, MJ Sattler, CA Dragan, YP Gast, WL Pitot, HC
Citation: Mj. Haas et al., Multiple polypeptide hormone expression in pancreatic islet cell carcinomas derived from phosphoenolpyruvatecarboxykinase-SV40 T antigen transgenic rats, PANCREAS, 20(2), 2000, pp. 206-214
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
Authors: Adjei, AA Erlichman, C Sloan, JA Reid, JM Pitot, HC Goldberg, RM Peethambaram, P Atherton, P Hanson, LJ Alberts, SR Jett, J
Citation: Aa. Adjei et al., Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors, J CL ONCOL, 18(8), 2000, pp. 1748-1757
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity
Authors: Adjei, AA Klein, CE Kastrissios, H Goldberg, RM Alberts, SR Pitot, HC Sloan, JA Reid, JM Hanson, LJ Atherton, P Rubin, J Erlichman, C
Citation: Aa. Adjei et al., Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity, J CL ONCOL, 18(5), 2000, pp. 1116-1123
Review article: the stages of gastrointestinal carcinogenesis - application of rodent models to human disease
Authors: Pitot, HC Hikita, H Dragan, Y Sargent, L Haas, M
Citation: Hc. Pitot et al., Review article: the stages of gastrointestinal carcinogenesis - application of rodent models to human disease, ALIM PHARM, 14, 2000, pp. 153-160
Hazard assessment of chemical carcinogens: the impact of hormesis
Authors: Teeguarden, JG Dragan, Y Pitot, HC
Citation: Jg. Teeguarden et al., Hazard assessment of chemical carcinogens: the impact of hormesis, J APPL TOX, 20(2), 2000, pp. 113-120
Nuclear-labeling index analysis (NLIA), a software package used to performaccurate automation of cell nuclear-labeling index analysis on immunohistochemically stained rat liver samples
Authors: Xu, YH Sattler, GL Edwards, H Pitot, HC
Citation: Yh. Xu et al., Nuclear-labeling index analysis (NLIA), a software package used to performaccurate automation of cell nuclear-labeling index analysis on immunohistochemically stained rat liver samples, COMPUT M PR, 63(1), 2000, pp. 55-70
Phase II study of paclitaxel and cisplatin for advanced urothelial cancer
Authors: Burch, PA Richardson, RL Cha, SS Sargent, DJ Pitot, HC Kaur, JS Camoriano, JK
Citation: Pa. Burch et al., Phase II study of paclitaxel and cisplatin for advanced urothelial cancer, J UROL, 164(5), 2000, pp. 1538-1542
Characterization of the major DNA adducts in the liver of rats chronicallyexposed to tamoxifen for 18 months
Authors: Firozi, PF Vulimiri, SV Rajaniemi, H Hemminki, K Dragan, Y Pitot, HC DiGiovanni, J Zhu, YH Li, DH
Citation: Pf. Firozi et al., Characterization of the major DNA adducts in the liver of rats chronicallyexposed to tamoxifen for 18 months, CHEM-BIO IN, 126(1), 2000, pp. 33-43
A north central cancer treatment group phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma
Authors: Pitot, HC Knost, JA Mahoney, MR Kugler, J Krook, JE Hatfield, AK Sargent, DJ Goldberg, RM
Citation: Hc. Pitot et al., A north central cancer treatment group phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma, CANCER, 89(8), 2000, pp. 1699-1705
Short-term fasting and the reversal of the stage of promotion in rat hepatocarcinogenesis: Role of cell replication, apoptosis, and gene expression
Authors: Hikita, H Vaughan, J Babcock, K Pitot, HC
Citation: H. Hikita et al., Short-term fasting and the reversal of the stage of promotion in rat hepatocarcinogenesis: Role of cell replication, apoptosis, and gene expression, TOXICOL SCI, 52(2), 1999, pp. 17-23
Quantitative analysis of dose- and time-dependent promotion of four phenotypes of altered hepatic foci by 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Sprague-Dawley rats
Authors: Teeguarden, JG Dragan, YP Singh, J Vaughan, J Xu, YH Goldsworthy, T Pitot, HC
Citation: Jg. Teeguarden et al., Quantitative analysis of dose- and time-dependent promotion of four phenotypes of altered hepatic foci by 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Sprague-Dawley rats, TOXICOL SCI, 51(2), 1999, pp. 211-223
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors
Authors: Pitot, HC McElroy, EA Reid, JR Windebank, AJ Sloan, JA Erlichman, C Bagniewski, PG Walker, DL Rubin, J Goldberg, RM Adjei, AA Ames, MM
Citation: Hc. Pitot et al., Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors, CLIN CANC R, 5(3), 1999, pp. 525-531
Preoperative hepatic artery chemoembolization followed by orthotopic livertransplantation for hepatocellular carcinoma
Authors: Harnois, DM Steers, J Andrews, JC Rubin, JC Pitot, HC Burgart, L Wiesner, RH Gores, GJ
Citation: Dm. Harnois et al., Preoperative hepatic artery chemoembolization followed by orthotopic livertransplantation for hepatocellular carcinoma, LIVER TR S, 5(3), 1999, pp. 192-199
Risultati: 1-25 | 26-35